Shanghai Runda Medical Technology (603108) Fundamentals 2026 — Revenue Analysis | SniperIQ
Shanghai Runda Medical Technology (603108) is a CN-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of ¥5.6B, trading at ¥9.23 on the SHH. This SniperIQ fundamentals page covers Shanghai Runda Medical Technology's valuation, profitability (net margin -7.8%), revenue (¥7.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Shanghai Runda Medical Technology's market cap?
Shanghai Runda Medical Technology (603108) has a market capitalization of approximately ¥5.6B, trading at ¥9.23 on the SHH. Market cap moves with the live share price.
What is Shanghai Runda Medical Technology's P/E ratio?
Shanghai Runda Medical Technology's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Shanghai Runda Medical Technology?
Shanghai Runda Medical Technology runs a net profit margin of -7.8%, a gross margin of 21.6%, and an operating margin of -3.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Shanghai Runda Medical Technology generate?
Shanghai Runda Medical Technology reported revenue of ¥7.0B for fiscal year 2025, with net income of -¥548M and earnings per share (EPS) of -0.91. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Shanghai Runda Medical Technology pay a dividend?
Shanghai Runda Medical Technology offers a trailing dividend yield of about 0.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Shanghai Runda Medical Technology financially healthy?
Shanghai Runda Medical Technology carries a debt-to-equity ratio of 1.88x and a current ratio of 1.08x, with a market beta of 0.59. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Shanghai Runda Medical Technology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Shanghai Runda Medical Technology (603108) the key facts are: market cap ¥5.6B, revenue ¥7.0B, 52-week range 8.7-21.1. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Shanghai Runda Medical Technology's full fundamentals live
Get Shanghai Runda Medical Technology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.